메뉴 건너뛰기




Volumn 26, Issue 8, 2016, Pages 1861-1868

Recent progress on third generation covalent EGFR inhibitors

Author keywords

Covalent inhibitor; Drug resistance; EGFR; Lung cancer; NSCLC; Oncogenic mutation; SBDD; T790M

Indexed keywords

ASP 8273; AZ 5104; AZ 7550; EGF 816; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HM 61713; OSIMERTINIB; PF 06747775; ROCILETINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

EID: 84960984325     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2016.02.067     Document Type: Review
Times cited : (93)

References (44)
  • 22
    • 84961732941 scopus 로고    scopus 로고
    • Abstracts of Papers, Boston, MA, United States, August 16-20, MEDI-340
    • Kath, J. C. Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015; MEDI-340.
    • (2015) 250th ACS National Meeting & Exposition
    • Kath, J.C.1
  • 27
  • 30
    • 84961712675 scopus 로고    scopus 로고
    • [abstract]. In Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR Abstract nr 1728
    • H. Sakagami, S. Konagai, H. Yamamoto, H. Tanaka, T. Matsuya, M. Mori, H. Koshio, M. Yuri, M. Hirano, and S. Kuromitsu [abstract]. In Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR Cancer Res. 74 2014 Abstract nr 1728
    • (2014) Cancer Res. , vol.74
    • Sakagami, H.1    Konagai, S.2    Yamamoto, H.3    Tanaka, H.4    Matsuya, T.5    Mori, M.6    Koshio, H.7    Yuri, M.8    Hirano, M.9    Kuromitsu, S.10
  • 33
    • 84961727881 scopus 로고    scopus 로고
    • American Society of Clinical Research, Abstr
    • Sequist, L. V. American Society of Clinical Research, 2015 Annual Meeting, Abstr. 8001.
    • 2015 Annual Meeting , pp. 8001
    • Sequist, L.V.1
  • 36
    • 84961685226 scopus 로고    scopus 로고
    • Tagrisso™ (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. AstraZeneca Press Release
    • Tagrisso™ (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. AstraZeneca Press Release.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.